A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
NCT ID: NCT01194375
Last Updated: 2012-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
180 participants
INTERVENTIONAL
2010-09-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low Strength IDP-107
Low Strength IDP-107
Once a day for 16 weeks
High Strength IDP-107
High Strength IDP-107
Once a day for 16 weeks
Placebo
Placebo
Once a day for 16 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low Strength IDP-107
Once a day for 16 weeks
High Strength IDP-107
Once a day for 16 weeks
Placebo
Once a day for 16 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of inflammatory and non-inflammatory lesions on the face
Exclusion Criteria
* Use of any systemic antibiotics or corticosteroids within 4 weeks prior to the Baseline visit
* Use of any systemic retinoids, such as isotretinoin, within 3 months prior to the Baseline visit
* Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dow Pharmaceutical Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatology Specialists, Inc.
Oceanside, California, United States
Horizons Clinical Research Center, LLC
Denver, Colorado, United States
North Florida Dermatology Associates, PA
Jacksonville, Florida, United States
FXM Research Corp.
Miami, Florida, United States
Ameriderm Research
Ormond Beach, Florida, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
The Indiana Clinical Trials Center, PC
Plainfield, Indiana, United States
Pedia Research LLC
Owensboro, Kentucky, United States
ActivMed Practices and Research, Inc.
Haverhill, Massachusetts, United States
Hamzavi Dermatology
Fort Gratiot, Michigan, United States
Minnesota Clinical Study Center
Fridley, Minnesota, United States
Comprehensive Clinical Research
Berlin, New Jersey, United States
Oregon Dermatology and Research Center
Portland, Oregon, United States
DermResearch, Inc.
Austin, Texas, United States
Dermatology Research Center, Inc.
Salt Lake City, Utah, United States
South Valley Dermatology
West Jordan, Utah, United States
Premier Clinical Research
Spokane, Washington, United States
Ultranova Skincare
Barrie, Ontario, Canada
The Centre for Dermatology and Cosmetic Surgery
Richmond Hill, Ontario, Canada
K. Papp Clinical Research
Waterloo, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DPSI-IDP-107-P2-02
Identifier Type: -
Identifier Source: org_study_id